New Weight Loss Drug Shows Promising Results

Recent studies suggest that experimental medications could potentially lead to weight loss of up to 20%. One such drug, called eloralintide, developed by Eli Lilly based in Indianapolis, has reportedly led to significant, dose-dependent weight loss in adults who are overweight or obese but without diabetes, as indicated by a recent press release.

Participants in the study generally tolerated the drug well. The Phase 2 trial, conducted by Eli Lilly, included 263 adults. Over a span of 48 weeks, these individuals lost between 9.5% and 20.1% of their body weight, compared to just 0.4% in the placebo group.

Furthermore, researchers observed various health improvements associated with eloralintide. These included reductions in waist circumference, blood pressure, lipid profiles, glycemic control, and inflammation markers, all linked to reduced cardiometabolic risks.

Dr. Liana K. Billings, the lead author of the study, highlighted the broader implications of these findings, noting that such weight loss could lead to the improvement or resolution of several conditions, such as high blood pressure and sleep apnea, among others, within just a year.

Interestingly, she also mentioned that participants did not reach a point where weight loss plateaued, suggesting that continued treatment could lead to further reductions in weight. Notably, around 90% of those who took eloralintide experienced an improvement in their BMI.

The results of this study were published in The Lancet and presented at ObesityWeek 2025 in Atlanta earlier this month. Eloralintide works differently from common drugs like Ozempic, Wegovy, and Mounjaro, by mimicking a hormone called amylin that the pancreas produces. This contrasts with GLP-1 (glucagon-like peptide 1) medications, which help regulate digestion and appetite.

As of now, the FDA has not yet approved eloralintide for clinical use. While the drug did show promising results, some mild to moderate gastrointestinal issues and fatigue were noted, especially at higher doses. Dr. Billings emphasized the need for a variety of treatments tailored to individual needs, given that obesity is a complex condition not easily addressed with a one-size-fits-all approach.

Plans for a Phase 3 clinical study of eloralintide are set in motion, aiming for a start by the end of the year. This will also include evaluations of the drug in combination with GLP-1 medications.

However, there are some concerns surrounding new anti-obesity drugs. Dr. Brett Osborne, a Florida neurosurgeon, shared that while medication can aid in weight loss, the integration of healthy habits and support from healthcare providers is crucial for sustainable results. He added that continued monitoring of new drugs like eloralintide over time is essential, as some side effects may not emerge until later.

Dr. Sue Decotis, a weight loss specialist in New York City, noted that targeting multiple receptor systems might enhance weight loss effectiveness. She observed improved outcomes in patients who switch from simpler drugs to those acting on more than one receptor.

As enthusiastic as some may be about new treatments, Whitney Di Bona, a consumer safety advocate with DrugWatch, warns that while the initial Phase 2 results are hopeful, ongoing caution is essential. She pointed out the emergence of new safety concerns, including potentially severe gastrointestinal issues and other complications that have led to various lawsuits over the years.

Ultimately, while the journey toward effective weight loss solutions is complex, new options like eloralintide could be a significant step forward. However, continuous research and patient monitoring remain vital as these newer treatments enter the market.